Castle Biosciences to Present at Upcoming Investor Conferences

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the following investor conferences later this month:

• Stephens Annual Investment Conference on Nov. 15, 2023, at 11:00 a.m. Eastern Time.
• Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Nov. 16, 2023, at 9:00 a.m. Eastern time.
• Piper Sandler 35th Annual Healthcare Conference on Nov. 28, 2023, at 12:30 p.m. Eastern time.

Live audio webcasts of the Company’s presentations will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. Replays of the webcasts will be available following the conclusion of the broadcasts.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231108949553/en/

Investor Contact:
Camilla Zuckero
[email protected]

Media Contact:
Allison Marshall
[email protected]

Source: Castle Biosciences Inc.

You May Also Be Interested In

• 3D Files Petition for Provisional Disposition Order Seeking Injunction Against the Invoking of Toho HD’s Poison Pill
• UNITE HERE Launches GraduateFails.org About AJ Capital Partners and Graduate by Hilton Hotels
• Temple’s Fademasterz Barber Academy Faces Scrutiny Over High Cost, Rigid Payment Rules, and Uncertain Payoff